Ascelia Pharma AB (ACE) Stock Statistics & Valuation Metrics

Ascelia Pharma AB has a market cap or net worth of kr433.36M. The enterprise value is ―.

Ascelia Pharma AB has 116,025,530 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascelia Pharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Ascelia Pharma AB is -1.04. Ascelia Pharma AB’s PEG ratio is -2.84.

In the last 12 months, Ascelia Pharma AB had revenue of 0.00 and earned -109.29M in profits. Earnings per share was -3.24.

In the last 12 months, operating cash flow was -62.84M and capital expenditures 0.00, giving a free cash flow of -62.84M billion.

Ascelia Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Ascelia Pharma AB upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.

Ascelia Pharma AB as a current ratio of 2.30, with Debt / Equity ratio of 32.17%

In the past 12 months, Ascelia Pharma AB has paid -319.00K in taxes.

Ascelia Pharma AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Ascelia Pharma AB has kr75.26M in cash and marketable securities with kr25.40M in debt, giving a net cash position of -kr49.86M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Ascelia Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―